457 related articles for article (PubMed ID: 29396092)
1. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial.
Kantarjian HM; Fenaux P; Sekeres MA; Szer J; Platzbecker U; Kuendgen A; Gaidano G; Wiktor-Jedrzejczak W; Carpenter N; Mehta B; Franklin J; Giagounidis A
Lancet Haematol; 2018 Mar; 5(3):e117-e126. PubMed ID: 29396092
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
[TBL] [Abstract][Full Text] [Related]
3. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
[TBL] [Abstract][Full Text] [Related]
4. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia.
Giagounidis A; Mufti GJ; Fenaux P; Sekeres MA; Szer J; Platzbecker U; Kuendgen A; Gaidano G; Wiktor-Jedrzejczak W; Hu K; Woodard P; Yang AS; Kantarjian HM
Cancer; 2014 Jun; 120(12):1838-46. PubMed ID: 24706489
[TBL] [Abstract][Full Text] [Related]
5. Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.
Fenaux P; Muus P; Kantarjian H; Lyons RM; Larson RA; Sekeres MA; Becker PS; Orejudos A; Franklin J
Br J Haematol; 2017 Sep; 178(6):906-913. PubMed ID: 28616874
[TBL] [Abstract][Full Text] [Related]
6. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
Tarantino MD; Bussel JB; Blanchette VS; Despotovic J; Bennett C; Raj A; Williams B; Beam D; Morales J; Rose MJ; Carpenter N; Nie K; Eisen M
Lancet; 2016 Jul; 388(10039):45-54. PubMed ID: 27103127
[TBL] [Abstract][Full Text] [Related]
7. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
[TBL] [Abstract][Full Text] [Related]
8. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Dodillet H; Kreuzer KA; Monsef I; Skoetz N
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine.
Greenberg PL; Garcia-Manero G; Moore M; Damon L; Roboz G; Hu K; Yang AS; Franklin J
Leuk Lymphoma; 2013 Feb; 54(2):321-8. PubMed ID: 22906162
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.
Kantarjian H; Fenaux P; Sekeres MA; Becker PS; Boruchov A; Bowen D; Hellstrom-Lindberg E; Larson RA; Lyons RM; Muus P; Shammo J; Siegel R; Hu K; Franklin J; Berger DP
J Clin Oncol; 2010 Jan; 28(3):437-44. PubMed ID: 20008626
[TBL] [Abstract][Full Text] [Related]
11. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial.
Lee JW; Lee SE; Jung CW; Park S; Keta H; Park SK; Kim JA; Oh IH; Jang JH
Lancet Haematol; 2019 Nov; 6(11):e562-e572. PubMed ID: 31474546
[TBL] [Abstract][Full Text] [Related]
12. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study.
Newland A; Godeau B; Priego V; Viallard JF; López Fernández MF; Orejudos A; Eisen M
Br J Haematol; 2016 Jan; 172(2):262-73. PubMed ID: 26537623
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy.
Kantarjian HM; Giles FJ; Greenberg PL; Paquette RL; Wang ES; Gabrilove JL; Garcia-Manero G; Hu K; Franklin JL; Berger DP
Blood; 2010 Oct; 116(17):3163-70. PubMed ID: 20631375
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials.
Prica A; Sholzberg M; Buckstein R
Br J Haematol; 2014 Dec; 167(5):626-38. PubMed ID: 25155450
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide.
Wang ES; Lyons RM; Larson RA; Gandhi S; Liu D; Matei C; Scott B; Hu K; Yang AS
J Hematol Oncol; 2012 Nov; 5():71. PubMed ID: 23190430
[TBL] [Abstract][Full Text] [Related]
16. Romiplostim for the management of perioperative thrombocytopenia.
Al-Samkari H; Marshall AL; Goodarzi K; Kuter DJ
Br J Haematol; 2018 Jul; 182(1):106-113. PubMed ID: 29767837
[TBL] [Abstract][Full Text] [Related]
17. Romiplostim or standard of care in patients with immune thrombocytopenia.
Kuter DJ; Rummel M; Boccia R; Macik BG; Pabinger I; Selleslag D; Rodeghiero F; Chong BH; Wang X; Berger DP
N Engl J Med; 2010 Nov; 363(20):1889-99. PubMed ID: 21067381
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.
Tarantino MD; Bussel JB; Blanchette VS; Beam D; Roy J; Despotovic J; Raj A; Carpenter N; Mehta B; Eisen M
Haematologica; 2019 Nov; 104(11):2283-2291. PubMed ID: 30846500
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes.
Sekeres MA; Kantarjian H; Fenaux P; Becker P; Boruchov A; Guerci-Bresler A; Hu K; Franklin J; Wang YM; Berger D
Cancer; 2011 Mar; 117(5):992-1000. PubMed ID: 20945323
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes.
Sekeres MA; Giagounidis A; Kantarjian H; Mufti GJ; Fenaux P; Jia C; Yang AS; Platzbecker U
Br J Haematol; 2014 Nov; 167(3):337-45. PubMed ID: 25039607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]